Comparison of the efficacy and retention of Natalizumab vs. Fingolimod in Cypriot patients with relapsing remitting multiple sclerosis.

被引：0
|
作者：
Kkolou, E. [1 ]
Leonidou, E. [1 ]
Gaglia, E. [1 ]
Pantzaris, M. [1 ]
机构：
[1] Cyprus Inst Neurol & Genet, Clin, Nicosia, Cyprus
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2016年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P11188
引用
收藏
页码：198 / 198
页数：1
相关论文
共 50 条
  • [1] Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis
    Roos, I.
    Sharmin, S.
    Ozakbas, S.
    Horakova, D.
    Havrdova, E. K.
    Boz, C.
    Alroughani, R.
    Patti, F.
    Terzi, M.
    Lechner-Scott, J.
    Izquierdo, G.
    Eichau, S.
    Grammond, P.
    Buzzard, K.
    Skibina, O.
    Prat, A.
    Girard, M.
    Duquette, P.
    Soysal, A.
    Grand'Maison, F.
    Kuhle, J.
    van der Walt, A.
    Butzkueven, H.
    Turkoglu, R.
    Butler, E.
    Laureys, G.
    van Hijfte, L.
    Shaygannejad, V.
    Yamout, B.
    Khoury, S.
    Prevost, J.
    Sidhom, Y.
    Gouider, R.
    Cartechini, E.
    Sanchez-Menoyo, J. L.
    Sa, M. Jose
    Macdonell, R.
    van Pesch, V.
    Ramo-Tello, C.
    McCombe, P.
    Willekens, B.
    Spitaleri, D.
    Ampapa, R.
    Al-Asmi, A.
    Slee, M.
    Besora, S.
    Malpas, C.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 778 - 780
  • [2] Six-month data on the safety and efficacy of Natalizumab in Cypriot patients with relapsing remitting multiple sclerosis
    Kkolou, E.
    Gagglia, E.
    Toufexis, J.
    Pantzaris, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 261 - 261
  • [3] The real-world efficacy of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An observational, multicentre Italian study
    Curti, E.
    Tsantes, E.
    Baldi, E.
    Caniatti, L.
    Ferraro, D.
    Sola, P.
    Granella, F.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 611 - 612
  • [4] Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis
    Kalincik, T.
    Horakova, D.
    Spelman, T.
    Jokubaitis, V.
    Trojano, M.
    Lugaresi, A.
    Izquierdo, G.
    Rozsa, C.
    Grammond, P.
    Alroughani, R.
    Duquette, P.
    Girard, M.
    Pucci, E.
    Lechner-Scott, J.
    Slee, M.
    Fernandez-Bolanos, R.
    Grand'Maison, F.
    Hupperts, R.
    Verheul, F.
    Hodgkinson, S.
    Oreja-Guevara, C.
    Spitaleri, D.
    Barnett, M.
    Terzi, M.
    Bergamaschi, R.
    McCombe, P.
    Sanchez-Menoyo, J.
    Simo, M.
    Csepany, T.
    Rum, G.
    Boz, C.
    Havrdova, E.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 195 - 196
  • [5] Regional efficacy of fingolimod in relapsing remitting multiple sclerosis
    Bogdan, I.
    Warren, C.
    Koniotes, A.
    Ruffer, G.
    Newell, B.
    Fisniku, L.
    Bremner, S.
    Gabel, M. C.
    Rashid, W.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 192 - 192
  • [6] Efficacy of natalizumab and fingolimod in relapsing-remitting multiple sclerosis in real world clinical practice
    Totaro, R.
    Costantino, G.
    Bellantonio, P.
    Danni, M.
    Di Carmine, C.
    Fantozzi, R.
    Cerqua, R.
    Fuiani, A.
    Mundi, C.
    Ruggieri, S.
    Marini, C.
    Provinciali, L.
    Carolei, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 267 - 267
  • [7] The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study
    Curti, Erica
    Tsantes, Elena
    Baldi, Eleonora
    Caniatti, Luisa Maria
    Ferraro, Diana
    Sola, Patrizia
    Granella, Franco
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 33 : 146 - 152
  • [8] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Boz, Cavit
    Ozakbas, Serkan
    Terzi, Murat
    Karabudak, Rana
    Sevim, Serhan
    Turkoglu, Recai
    Soysal, Aysun
    Balci, Belgin Petek
    Efendi, Husnu
    Turan, Omer Faruk
    Yuceyar, Nur
    Yetkin, Mehmet Fatih
    Karahan, Serap Zengin
    Demirkiran, Meltem
    Guler, Sibel
    Agan, Kadriye
    Kiylioglu, Nefati
    Baba, Cavid
    Tuncer, Asli
    Koseoglu, Mesrure
    NEUROLOGICAL SCIENCES, 2023, 44 (06) : 2121 - 2129
  • [9] Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis
    Sharmin, S.
    Lefort, M.
    Andersen, J.
    Horakova, D.
    Havrdova, E. K.
    Alroughani, R.
    Izquierdo, G.
    Eichau, S.
    Ozakbas, S.
    Butzkueven, H.
    Patti, F.
    Onofrj, M.
    Lugaresi, A.
    Terzi, M.
    Grammond, P.
    Grand'Maison, F.
    Yamout, B.
    Prat, A.
    Girard, M.
    Duquette, P.
    Boz, C.
    Trojano, M.
    McCombe, P.
    Slee, M.
    Lechner-Scott, J.
    Turkoglu, R.
    Sola, P.
    Ferraro, D.
    Granella, F.
    Shaygannejad, V.
    Prevost, J.
    Skibina, O.
    Solaro, C.
    Karabudak, R.
    Van Wijmeersch, B.
    Csepany, T.
    Spitaleri, D.
    Vucic, S.
    Leray, E.
    Sorensen, P. S.
    Sellebjerg, F.
    Magyari, M.
    Vukusic, S.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 786 - 788
  • [10] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Cavit Boz
    Serkan Ozakbas
    Murat Terzi
    Rana Karabudak
    Serhan Sevim
    Recai Turkoglu
    Aysun Soysal
    Belgin Petek Balcı
    Hüsnü Efendi
    Ömer Faruk Turan
    Nur Yüceyar
    Mehmet Fatih Yetkin
    Serap Zengin Karahan
    Meltem Demirkıran
    Sibel Guler
    Kadriye Agan
    Nefati Kıylıoğlu
    Cavid Baba
    Asli Tuncer
    Mesrure Köseoğlu
    Neurological Sciences, 2023, 44 : 2121 - 2129
12345